– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease caused by problems in the body's complement system, which normally helps fight infections. It damages tiny filters in your kidneys called ...
Novartis’ kidney disease troika keeps marching forward. With a new FDA approval, the company’s Fabhalta has become the first treatment endorsed by the agency for the ultrarare kidney disease ...
Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. The FDA Wednesday granted an accelerated approval to Novartis’ Fabhalta in IgAN. The ...
Coming to grips with the semantics and vocabulary that apply to “distortion” takes a little discipline, but it isn’t all that intimidating. All you need is a little patience to go over the relevant ...
The U.S. FDA has approved Novartis AG’s Fabhalta (iptacopan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disease that impairs blood cell production.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback